Press "Enter" to skip to content

New patent for Novartis drug KISQALI FEMARA CO-PACK (COPACKAGED)

4
Copyright © DrugPatentWatch. Originally published at New patent for Novartis drug KISQALI FEMARA CO-PACK (COPACKAGED)

Annual Drug Patent Expirations for KISQALI+FEMARA+CO-PACK+%28COPACKAGED%29
Annual Drug Patent Expirations for KISQALI+FEMARA+CO-PACK+%28COPACKAGED%29

Kisqali Femara Co-pack (copackaged) is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug.

This drug has one hundred and thirty-six patent family members in fifty countries.

The generic ingredient in KISQALI FEMARA CO-PACK (COPACKAGED) is letrozole; ribociclib succinate. One supplier is listed for this compound. Additional details are available on the letrozole; ribociclib succinate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Novartis drug KISQALI FEMARA CO-PACK (COPACKAGED)
Online Certificate Course

Decision-Making for Generic Drug Entry & Branded Drug Lifecycle Management

  • When will key drug patents expire?
  • How can I find, evaluate, and plan for generic market entry opportunities?
  • How can I find proprietary out-of-court settlements and deal terms?
DrugPatentWatch - Make Better Decisions